Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1


      Objective. Δ9-Tetrahydrocannabinol, the active agent of Cannabis sativa, exhibits well-documented antitumor properties, but little is known about the possible effects mediated by endogenous cannabinoids on human tumors. In the present study, we analyzed the effect of arachidonyl ethanolamide (AEA) on cervical carcinoma (CxCa) cell lines.
      Methods. To assess the sensitivity of CxCa cells to AEA, we selected three cell lines that were exposed to increasing doses of AEA with or without antagonists to receptors to AEA. DNA fragmentation and caspase-7 activity were used as apoptosis markers. The expression of receptors to AEA were analyzed in CxCa cell lines as well as CxCa biopsies.
      Results. The major finding was that AEA induced apoptosis of CxCa cell lines via aberrantly expressed vanilloid receptor-1, whereas AEA binding to the classical CB1 and CB2 cannabinoid receptors mediated a protective effect. Furthermore, unexpectedly, a strong expression of the three forms of AEA receptors was observed in ex vivo CxCa biopsies.
      Conclusion. Overall, these data suggest that the specific targeting of VR1 by endogenous cannabinoids or synthetic molecules offers attractive opportunities for the development of novel potent anticancer drugs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Matsuda L.A.
        • Lolait S.J.
        • Brownstein M.J.
        • Young A.C.
        • Bonner T.I.
        Structure of a cannabinoid receptor and functional expression of the cloned cDNA.
        Nature. 1990; 346: 561-564
        • Kaminski N.E.
        • Abood M.E.
        • Kessler F.K.
        • Martin B.R.
        • Schatz A.R.
        Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation.
        Mol. Pharmacol. 1992; 42: 736-742
        • Devane W.A.
        • Hanus L.
        • Breuer A.
        • Pertwee R.G.
        • Stevenson L.A.
        • Griffin G.
        • et al.
        Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
        Science. 1992; 258: 1946-1949
        • Glass M.
        • Felder C.C.
        Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
        J. Neurosci. 1997; 17: 5327-5333
        • Bayewitch M.
        • Avidor-Reiss T.
        • Levy R.
        • Barg J.
        • Mechoulam R.
        • Vogel Z.
        The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
        FEBS Lett. 1995; 375: 143-147
        • Munro S.
        • Thomas K.L.
        • Abu-Shaar M.
        Molecular characterization of a peripheral receptor for cannabinoids.
        Nature. 1993; 365: 61-65
        • Galve-Roperh I.
        • Sanchez C.
        • Cortes M.L.
        • del Pulgar T.G.
        • Izquierdo M.
        • Guzman M.
        Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.
        Nat. Med. 2000; 6: 313-319
        • Sanchez C.
        • de Ceballos M.L.
        • del Pulgar T.G.
        • Rueda D.
        • Corbacho C.
        • Velasco G.
        • et al.
        Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
        Cancer Res. 2001; 61: 5784-5789
        • De Petrocellis L.
        • Melck D.
        • Palmisano A.
        • Bisogno T.
        • Laezza C.
        • Bifulco M.
        • et al.
        The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
        Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8375-8380
        • Melck D.
        • De Petrocellis L.
        • Orlando P.
        • Bisogno T.
        • Laezza C.
        • Bifulco M.
        • et al.
        Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
        Endocrinology. 2000; 141: 118-126
        • Jacobsson S.O.
        • Wallin T.
        • Fowler C.J.
        Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.
        J. Pharmacol. Exp. Ther. 2001; 299: 951-959
        • Maccarrone M.
        • Lorenzon T.
        • Bari M.
        • Melino G.
        • Finazzi-Agro A.
        Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors.
        J. Biol. Chem. 2000; 275: 31938-31945
        • Zygmunt P.M.
        • Petersson J.
        • Andersson D.A.
        • Chuang H.
        • Sorgard M.
        • Di Marzo V.
        • et al.
        Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.
        Nature. 1999; 400: 452-457
        • Campbell V.A.
        Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation.
        Neuropharmacology. 2001; 40: 702-709
        • Wolvetang E.J.
        • Larm J.A.
        • Moutsoulas P.
        • Lawen A.
        Apoptosis induced by inhibitors of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin.
        Cell Growth Differ. 1996; 7: 1315-1325
        • Rueda D.
        • Galve-Roperh I.
        • Haro A.
        • Guzman M.
        The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.
        Mol. Pharmacol. 2000; 58: 814-820
        • Koutsky L.A.
        • Ault K.A.
        • Wheeler C.M.
        • Brown D.R.
        • Barr E.
        • Alvarez F.B.
        • et al.
        • Proof of Principle Study Investigators
        A controlled trial of a human papillomavirus type 16 vaccine.
        N. Engl. J. Med. 2002; 347: 1645-1651
        • McIntyre P.
        • McLatchie L.M.
        • Chambers A.
        • Phillips E.
        • Clarke M.
        • Savidge J.
        • et al.
        Pharmacological differences between the human and rat vanilloid receptor 1 (VR1).
        Br. J. Pharmacol. 2001; 132: 1084-1094
        • Rinaldi-Carmona M.
        • Barth F.
        • Heaulme M.
        • Alonso R.
        • Shire D.
        • Congy C.
        • et al.
        Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
        Life Sci. 1995; 56: 1941-1947
        • Rinaldi-Carmona M.
        • Barth F.
        • Millan J.
        • Derocq J.M.
        • Casellas P.
        • Congy C.
        • et al.
        SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
        J. Pharmacol. Exp. Ther. 1998; 284: 644-650
        • Van der Stelt M.
        • Veldhuis W.B.
        • van Haaften G.W.
        • Fezza F.
        • Bisogno T.
        • Bar P.R.
        • et al.
        Exogenous anandamide protects rat brain against acute neuronal injury in vivo.
        J. Neurosci. 2001; 21: 8765-8771
        • Bifulco M.
        • Di Marzo V.
        Targeting the endocannabinoid system in cancer therapy: a call for further research.
        Nat. Med. 2002; 8: 547-550